Basilea Pharmaceutica (XSWX:BSLN) Moat Score: 5/10 (As of Jul. 03, 2026)


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
61 GF Score
Price CHF53.10
GF Value CHF57.51
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Moat Score?

Basilea Pharmaceutica XSWX:BSLN +0.38% 61 Moat Score is 5 as of Jul. 03, 2026. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.51 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,399 Biotechnology companies, Basilea Pharmaceutica ranks better than 96.71% on this metric.

Basilea Pharmaceutica has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Basilea Pharmaceutica has Narrow Moat: Basilea Pharmaceutica Ltd has a solid narrow moat due to its valuable intellectual property and patents in the pharmaceutical industry. However, it faces intense competition and lacks significant network effects or cost advantages to elevate it to a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Basilea Pharmaceutica might have Narrow Moat - Solid narrow moat.

Basilea Pharmaceutica  (XSWX:BSLN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Basilea Pharmaceutica Moat Score Related Terms

XSWX:BSLN vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basilea Pharmaceutica Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Moat Score distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Moat Score falls into.


XSWX:BSLN
61GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Moat Score of 5 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Basilea Pharmaceutica ranks #46 out of 1399 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Basilea Pharmaceutica's Moat Score too high?
Basilea Pharmaceutica's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Basilea Pharmaceutica's value of 5 is 150% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #46 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #46 out of 1399 companies for Moat Score. This places Basilea Pharmaceutica in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Basilea Pharmaceutica's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.51, compared to a current price of CHF53.10 — trading 7.7% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Moat Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF53.10 is trading 7.7% below its estimated GF Value™ of CHF57.51. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Moat Score: 5
  • GF Value™: CHF57.51 vs. price of CHF53.10 (7.7% below fair value)
  • GF Score™: 61/100 with 2 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1399)

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for XSWX:BSLN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF53.10
Price
CHF57.51
GF Value